Welcome to our dedicated page for ZyVersa Therapeutics SEC filings (Ticker: ZVSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a clinical-stage biotech like ZyVersa Therapeutics (ZVSA) means sorting through pages of trial data, licensing clauses and cash-runway footnotes. Those details hide in 10-Ks, 10-Qs and rapid-fire 8-Ks—and missing one update could upend a valuation model. Stock Titan pulls every ZyVersa insider trading Form 4 transactions notice, each lab milestone buried in an 8-K and the latest ZyVersa quarterly earnings report 10-Q filing into one constantly refreshed dashboard.
Our AI engine reads every paragraph the moment it hits EDGAR, then delivers plain-English answers to questions investors actually ask: "Is burn rate accelerating?", "Which directors just filed a ZyVersa Form 4 insider transactions real-time?", "What new risk factors surfaced in the ZyVersa annual report 10-K simplified?". You’ll also find annotated sections that map trial expenses to pipeline stages, highlight royalty obligations, and decode the ZyVersa proxy statement executive compensation so you can compare R&D spend to management incentives without scrolling through dense footnotes.
Whether you need ZyVersa 8-K material events explained before the market opens, a ZyVersa earnings report filing analysis for your model, or help understanding ZyVersa SEC documents with AI, Stock Titan’s platform covers every form type: real-time Form 4 alerts, condensed 10-Q summaries, deep-dive 10-K analytics, and side-by-side trend charts. Skip the PDF hunt—get the trial timelines, patent updates and ZyVersa executive stock transactions Form 4 data that drive biotech valuations in minutes, not hours.
ZyVersa Therapeutics, Inc. reported that independent director Robert G. Finizio has resigned from the company’s Board of Directors, effective immediately. He also stepped down as Chairman of the Compensation Committee and as a member of the Audit Committee. The company states that his resignation is due to personal reasons and is not the result of any disagreement regarding ZyVersa’s operations, policies, or practices. ZyVersa’s common stock, par value $0.0001 per share, is quoted on the OTCQB Venture Market under the symbol ZVSA.
ZyVersa Therapeutics, Inc. (ZVSA) filed a current report to announce that it released a press release with its unaudited financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is being furnished rather than filed, which means it is not automatically subject to certain liability provisions under the securities laws or incorporated into other securities filings unless specifically referenced. The company’s common stock, par value $0.0001 per share, trades under the symbol ZVSA and is quoted on the OTCQB Venture Market.
ZyVersa Therapeutics, Inc. reported a sharply higher Q3 2025 loss driven by a major write-down of R&D assets and continued cash burn. Net loss for the quarter was $19.8 million versus $2.4 million a year earlier, and $24.3 million for the nine months versus $8.0 million, largely due to an $18.6 million impairment of in-process research and development after a sustained decline in market capitalization.
Operating expenses rose to $20.8 million in Q3 2025 from $2.3 million, while research and development and general and administrative costs both declined year over year. Cash was $0.5 million at September 30, 2025, with a working capital deficit of $11.8 million and an accumulated deficit of $136.9 million. The company used $4.7 million of cash in operations over nine months and raised $3.7 million via a March 2025 private warrant placement and a July 2025 warrant inducement.
Management states that these conditions raise substantial doubt about ZyVersa’s ability to continue as a going concern. In July 2025, Nasdaq denied continued listing, and the common stock was delisted on October 6, 2025; trading moved to the OTCQB under the symbol ZVSA.
ZyVersa Therapeutics filed a Form 12b-25, indicating it cannot submit its Quarterly Report on Form 10‑Q for the quarter ended September 30, 2025 without unreasonable effort or expense. The company expects to file within the five‑day extension period permitted under Rule 12b‑25.
The company stated it is completing management’s review of its quarter‑end consolidated financial statements and related disclosures. It also disclosed that the results to be included in the Form 10‑Q will reflect significant changes in net loss from the prior‑year period due to an $18.6 million non‑cash impairment charge related to in‑process research and development. Forward‑looking statements caution that actual timing and outcomes may differ.
ZyVersa Therapeutics announced a leadership change. On October 10, 2025, Pablo Guzman, M.D., resigned as Chief Medical Officer and Senior Vice President of Medical Affairs. Dr. Guzman joined the company in January 2015 after more than 35 years practicing interventional cardiology in South Florida and serving as a managing partner of Cardiology Associates of Fort Lauderdale. The company states he resigned to spend more time with his family and to travel.
ZyVersa Therapeutics, Inc. (ZVSA) submitted a Form 25 notice indicating removal of its securities from listing and/or registration on the Nasdaq Stock Market LLC. The filing identifies the issuer's principal office in Weston, Florida, and provides a contact telephone number. The form lists the regulatory provisions for voluntary or exchange-initiated delisting under 17 CFR 240.12d2-2 and certifies Nasdaq's compliance with the rule for striking the class from listing and/or registration.
FAQ
What is the current stock price of ZyVersa Therapeutics (ZVSA)?
What is the market cap of ZyVersa Therapeutics (ZVSA)?
